INVUITY(R) PhotonBlade(TM), REF PB1
Published August 2, 2017 · Recall initiated: June 12, 2017
Summary
FDA records medical device Class II recall Z-2778-2017, published August 2, 2017 and initiated June 12, 2017. Recalling firm: Invuity, Inc.; Status: Terminated; Reported quantity: 1328 units; Lot: All Lot Numbers. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
A small number of customer observations were recently received which related to possible unintended energy discharge with the potential to cause tissue damage to patients.
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Invuity, Inc.
- Distributor
- nationwide
- Lot
- All Lot Numbers
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAAmantadine HCl Capsules, USP, 100 mg, Rx Only, 50 Capsules (5x10) Unit Dose Cartons, Manufactured for: AvKAREAugust 9, 2017
- FDACyclobenzaprine HCl Tablets, USP, 5 mg, 50 Tablets (5x10) Unit Dose Cartons, Rx Only, Manufactured for: AvKAREAugust 9, 2017
- FDASTOCKERT Heater-Cooler System 3T, 120V/60 HzAugust 2, 2017
- FDASTOCKERT Heater-Cooler System 3T, 208V/60 HzAugust 2, 2017
- FDASTOCKERT Heater-Cooler System 3T, 240V/60 HzAugust 2, 2017
- FDABriteField illuminated Suction Device; Model numbers 8Fr, 10Fr and 12Fr, Kit (included 8Fr, 10Fr and 12Fr andOctober 10, 2012
Questions about this recall
Was INVUITY(R) PhotonBlade(TM), REF PB1 recalled?
Yes. FDA published recall Z-2778-2017 on August 2, 2017. Reported hazard: A small number of customer observations were recently received which related to possible unintended energy discharge with the potential to cause tissue damage to patients.
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit